Edinburgh-based Craneware plc, a provider of “healthcare financial performance solutions” for the US healthcare market, said its revenue rose 6% to $105.7 million in the six months to December 31, 2025, while adjusted profit before tax rose 14% to $23.5 million.

Craneware said it intends to commence a share buyback programme of $25 million.

The firm’s revenue is derived almost entirely from the sale of software licences, professional services and transactional fees to hospitals and affiliated pharmacies within the United States.

Craneware CEO Keith Neilson said: “High levels of expansion sales, healthy NRR and an increasing 340B Shelter opportunity underpin our confidence in a positive second half performance.

“The increasing levels of competitive wins and takeouts we have seen in the first half of the year demonstrate the importance of the Trisus platform, the benefit of our independence to our hospital customers and our ability to leverage AI in combination with our extensive proprietary data sets to deliver the solutions our customers need, when they need them.

“These unique strengths underpin future revenue growth acceleration and sustainable, long-term value generation.

“The US healthcare market continues to evolve at pace, and with each new piece of legislation or change, the need for data-led insights and a secure and scalable technology partner grows.

“We have never been more confident in the vital role we play in enabling our customers to navigate these changes with confidence, while maintaining their financial strength and delivery of care. This is a hugely powerful motivator for all of us at The Craneware Group.

“With our wealth of proprietary data, deep industry expertise, longstanding and extensive customer base, and growing AI capabilities, the Board looks to the future with confidence.”